Merus (NASDAQ: MRUS), focused on the development of innovative, full-length multispecific antibodies, has closed an underwritten public offering of 5,575,757 shares of common stock, including an additional 727,272 shares per the full exercise of the over-allotment option granted to the underwriters. Merus secured approximately $138 million in gross proceeds, with each of the shares sold at the public offering price of $24.75. The company intends to use the proceeds to advance clinical development of its product candidates, for preclinical research and technology development, as well as for working capital and general corporate purposes. ROTH Capital Partners acted as co-manager for the offering.
To view the full press release, visit https://ibn.fm/soGVC
About Merus N.V.
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics(R). Multiclonics(R) are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For more information, please visit www.Merus.nl.
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.